本研究一共收集了392位第二型糖尿病患者 (235位女性 147位男性)接受胃袖狀切除手術有87位，接受胃繞道手術有305位，術後ㄧ年追蹤資料。前瞻性研究，腦部及冠心病危險性用英國預測糖尿病研究風險引擎作為評估。結果由不同術式做為分組。
Metabolic surgery ameliorates cardiovascular risk in obese diabetic patients: Influence of different surgical procedures
The current study confirms the significant reduction of the CVD risk of up to 50% after one year of surgery.
Metabolic surgery confirms the well remission of type 2 diabetes mellitus after one year of surgery.
The sleeve gastrectomy before surgery was the independent predictor of CVD risk reduction after MS.
Gastric bypass surgery carries a higher power on CVD risk reduction than SG.
In recent years, bariatric surgery was found to have therapeutic potential for the treatment of type 2 diabetes (T2D) in severely obese patients (body mass index [BMI] ≥35 kg/m2) and to reduce cardiovascular disease (CVD) risk and mortality. However, the benefit of CVD risk reduction after metabolic surgery in nonseverely obese T2D patients (BMI <35 kg/m2) remained to be proven.
To evaluate the CVD risk after metabolic surgery in T2D patients using The UK Prospective Diabetes Study score.
Tertiary referral general hospital, Taiwan, Republic of China.
Outcomes of 392 patients (235 women and 147 men) who had undergone sleeve gastrectomy (87) or gastric bypass (305) for treatment of T2D with 1-year follow-up were assessed. Data were prospectively collected for study, and cerebral and coronary heart disease risk was calculated by using The UK Prospective Diabetes Study risk engine. Outcomes of patients who had undergone different surgical procedures were assessed.
One year after surgery, weight and glycemic control with complete and partial remission of T2D were significant in most of the patients. The 10-year coronary heart disease risk and fatal coronary heart disease risk were also reduced from 8.8% to 4.6% and from 4.6% to 2.1%, respectively (both P < .001). Similar CVD risk reduction was seen in both patients with BMI ≥35 and BMI <35. Multivariable analysis confirmed that surgical procedure of sleeve gastrectomy was a negative independent predictor of CVD risk reduction after metabolic surgery.
The present study confirms the efficacy of metabolic surgery for the T2D treatment and reduction of CVD risk up to 50% 1 year after surgery. Gastric bypass surgery has more power on CVD risk reduction than sleeve gastrectomy.